Bio-Responsive and Immune Protein-Based Therapies for Inhibition of Proteolytic Enzymes in Dental Tissues
Project Number5R01DE032302-02
Contact PI/Project LeaderPIOVEZAN FUGOLIN, ANA PAULA
Awardee OrganizationOREGON HEALTH & SCIENCE UNIVERSITY
Description
Abstract Text
SUMMARY
This multidisciplinary proposal translates the efforts of a highly skilled group of researchers forging unprecedented
pathways to promote hard and soft dental tissues preservation. Cutting-edge strategies inspired in approaches used in
the medical field are employed to inhibit selectively endogenous metalloproteinases responsible for mediating the
degradation of the collagen. In Dentistry, the destruction of this essential component of the extracellular matrix is strongly
associated with the progression of periodontal disease and the breakdown of the dental substrate/restorative material
interface leading to bacteria recolonization and recurrent caries, the primary cause of failure of dental restorations. These
pathological conditions together are responsible for almost 80% of the tooth extractions in the United States. In order to
address this serious public health issue, two innovative platforms are proposed. The first strategy is based on the
encapsulation of two potent MMP inhibitors, the polyphenols quercetin and epigallocatechin gallate, in nano micelles
cleavable by MMPs. The shell of the particles is composed of peptides with specific sequences of amino acids recognized
and cleaved by the targeted MMPs, leading to rupture of the micelles and the release of the inhibitor molecules. In
essence, this system enables the MMP to inhibit itself. The second strategy is an immunomodulatory platform based on
the introduction of anti-MMP nanobodies, single domain antibodies derived from llama heavy-chain only antibodies, to
inhibit/cease MMP proteolytic activity. As nanoparticles or nanobodies delivery vehicles, a dental primer formulation and
a newly-designed multifunctional hydrogel are used for the adhesive interface and periodontal pockets, respectively. To
validate the designed platforms, tooth-on-a-chip and animal models are being added in order to fast-track their translation
into clinical care. The innovation of this proposal stems from: (1) the employment of a pioneering approach to inactivate
MMPs in dental tissues based on enzymatic-responsive nanoparticles to deliver inhibitors, and (2) the introduction of a
new paradigm based on the modulation of the MMPs activity by nanobody technology. After completing this project, we
will have these two platforms tailored and validated to be delivered in vehicles compatible with the current clinical
techniques employed to treat periodontitis and to hybridize the dentin during the restorative procedures, which will allow
to bridge the gap between cutting-edge research and improved patient care. In addition, these platforms can be either
combined or tailored in more complex and multi-functional entities and programmed to respond to a variety of enzymes
and cytokines, which provides new opportunities to develop innovative dental tissue regeneration/preservation
therapeutics to minimize tooth loss especially in highly vulnerable population.
Public Health Relevance Statement
NARRATIVE
Collagen degradation mediated by proteolytic endogenous enzymes is strongly associated with the progression
of periodontal disease and the breakdown of the dental substrate/restorative material interface, which together are the
cause for almost 80% of the tooth extractions in the United States. This project aims to develop two independent cutting-
edge platforms based on polyphenols sequestered in enzyme-responsive nanomicelles and nanobodies immune proteins,
in order to modulate metalloproteinases (MMPs) -2, -8, and -9 activity in periodontal pockets and at dentin-adhesive
interfaces and, ultimately, prevent/cease undesirable dental tissues. It is expected that this proposal leads to the
development of biologically-responsive and immunomodulatory-based dental biomaterials capable of suppressing the
collagen enzymatic degradation activity in different therapeutic niches while addressing the NIDCR priorities to develop
interdisciplinary, unique, and innovative approaches to promote oral health.
National Institute of Dental and Craniofacial Research
CFDA Code
121
DUNS Number
096997515
UEI
NPSNT86JKN51
Project Start Date
17-March-2023
Project End Date
28-February-2028
Budget Start Date
01-March-2024
Budget End Date
28-February-2025
Project Funding Information for 2024
Total Funding
$628,082
Direct Costs
$408,420
Indirect Costs
$219,662
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Dental and Craniofacial Research
$628,082
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01DE032302-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01DE032302-02
Patents
No Patents information available for 5R01DE032302-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01DE032302-02
Clinical Studies
No Clinical Studies information available for 5R01DE032302-02
News and More
Related News Releases
No news release information available for 5R01DE032302-02
History
No Historical information available for 5R01DE032302-02
Similar Projects
No Similar Projects information available for 5R01DE032302-02